No heterogeneity of the glycaemic response was observed according to age (< > 65 years), diabetes duration (< > 10 years), BMI (< > 30 kg/m2), presence of CKD stage III or higher, microangiopathy, macroangiopathy, or concomitant treatment with SGLT-2 inhibitors (Fig. 3). Here, SLC5A2 is linked to chronic kidney disease.